Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

Alopexx, Provenance Ink $8M Deal for Anticancer Immunotherapeutic

Firms will establish company to continue development of Provenance’s Phase I-stage DI-Leu16-IL2 against hematologic cancers.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll